Form 4: Lilly Director Acquires Stock Units

Eli Lilly Director J. Erik Fyrwald acquired stock units valued at $1,129.35 as part of a deferred compensation plan.

Summary

• J. Erik Fyrwald, a Director at Eli Lilly & Co. (LLY), acquired 8.7809 units of common stock on June 15, 2026.
• These shares were acquired as stock units under the Lilly Directors' Deferral Plan, in lieu of cash compensation.
• The acquisition has a value of $1,129.35.
• Following this transaction, Fyrwald beneficially owns 75,401.0968 shares of common stock directly.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, as it represents a director's participation in a standard deferred compensation plan, indicating ongoing commitment rather than a significant new investment or divestment.

Positives

• Director J. Erik Fyrwald's acquisition of stock units indicates continued investment and confidence in the company.
• The acquisition is part of a structured deferral plan, suggesting a long-term commitment rather than a speculative trade.

Future Outlook

The acquired stock units will be settled in shares of common stock following the reporting person's separation from service, indicating a long-term holding strategy.

Industry Context

StockSavvy.ai notes that insider transactions, particularly those involving directors acquiring stock or stock units, are often viewed as a signal of management's confidence in the company's future prospects within the pharmaceutical industry.

Corporate Governance

Stakeholder Impact

• Shareholders: The transaction may be viewed positively as it demonstrates a director's continued investment and commitment to the company's long-term success.

Next Steps

• Settlement of acquired stock units in shares of common stock following the reporting person's separation from service.

Key Dates

Keywords

Eli Lilly, LLY, Form 4, Insider Trading, Director, Stock Units, Deferred Compensation